Actimmune Registry

PreclinicalSmall molecule

IInterMune

Actimmune Registry is one of 3 small molecule programs targeting Osteopetrosis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

OsteopetrosisActive, not recruiting

OsteopetrosisPreclinical

Active, not recruiting

Competition

Competitive Landscape

2 competitors in Osteopetrosis

#DrugCompanyPhaseTrials

Clolar

GGenzyme, a Sanofi Company

Actimmune Registry

1 3

Systemic Chemotherapy and Antibodies

SSt. Jude Children's Research Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Osteopetrosis1 trial

Post Marketing Surveillance Study of Actimmune in Patients With Severe, Malignant Osteopetrosis

Completed·IInterMune··NCT00043329·6 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Actimmune Registry. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Actimmune Registry compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Actimmune Registry. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — InterMune company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: IInterMune

Actimmune Registry

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Osteopetrosis1 trial

References

Drug Info

Quick Facts

Related News